Medical information Clinical review pending

Genetic Testing

RET Gene Multiple Endocrine Neoplasia Type 2B Genetic Test

This genetic test identifies mutations in the RET gene associated with Multiple Endocrine Neoplasia Type 2B (MEN2B), a condition increasing the risk of specific cancers. It helps in early diagnosis and management for individuals at risk.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample (EDTA tube), Extracted DNA, or One drop of blood on FTA Card.
Results: Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation: Provide a detailed clinical and family history. A genetic counseling session prior to testing is recommended to discuss the implications and create a family pedigree.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the RET Gene Multiple Endocrine Neoplasia Type 2B Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Family history of Multiple Endocrine Neoplasia Type 2B (MEN2B).
✓Family history of medullary thyroid carcinoma (MTC) or pheochromocytoma.
✓Personal history suggestive of MEN2B symptoms (e.g., thyroid nodules, abdominal pain, headaches, diarrhea, flushing).
✓Confirmation of diagnosis in individuals with clinical features suggestive of MEN2B.
✓Family member identified with a RET gene mutation.

In plain language

What this test helps you understand

This test helps identify individuals with mutations in the RET gene, which are causative for MEN2B. Early identification allows for proactive monitoring and management strategies to reduce the risk and impact of associated cancers, such as medullary thyroid carcinoma and pheochromocytoma.

The RET Gene Multiple Endocrine Neoplasia Type 2B (MEN2B) Genetic Test is designed to detect specific genetic mutations in the RET gene. These mutations are known to cause MEN2B, a hereditary condition that significantly increases the risk of developing certain cancers, most notably medullary thyroid carcinoma and pheochromocytoma. Understanding your genetic risk through this test can empower you and your healthcare provider to make informed decisions about proactive health management and early intervention strategies. This test utilizes Next-Generation Sequencing (NGS) technology for a comprehensive analysis of the RET gene.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationProvide a detailed clinical and family history. A genetic counseling session prior to testing is recommended to discuss the implications and create a family pedigree.

SampleBlood sample (EDTA tube), Extracted DNA, or One drop of blood on FTA Card.

MethodologyNext-Generation Sequencing (NGS) is used to analyze the RET gene for specific mutations associated with MEN2B.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test specifically analyzes the RET gene for mutations associated with MEN2B. It does not detect mutations in other genes that may cause similar conditions. A negative result does not completely rule out the possibility of a genetic predisposition if the specific mutation is not detected or if another gene is involved. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

MEN2B is a rare inherited disorder that increases the risk of developing specific types of tumors, particularly medullary thyroid carcinoma and pheochromocytoma.

Individuals with a family history of MEN2B, medullary thyroid carcinoma, or pheochromocytoma, or those exhibiting symptoms suggestive of the condition, should consider testing.

A positive result indicates the presence of a mutation in the RET gene associated with MEN2B. This means the individual has an increased risk of developing related cancers and requires specific medical monitoring and management.

A negative result means no RET mutations associated with MEN2B were detected in the sample. However, it's important to discuss the result with a healthcare provider, as other factors might still influence risk.

Yes, genetic counseling before and after testing is highly recommended to understand the test's implications, interpret results, and discuss management options.

A sample can be collected as a blood draw, using extracted DNA, or via a single drop of blood on an FTA card.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp